SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER

被引：0
|
作者：
Gerber, David [1 ]
Infante, Jeffrey [2 ]
Gordon, Michael [3 ]
Schiller, Joan [1 ]
Spigel, David [4 ]
Wang, Yulei [5 ]
Shames, David S. [5 ]
Choi, Younjeong [5 ]
Kahn, Robb [5 ]
Xu, Jian [5 ]
Lin, Kedan [5 ]
Wood, Katie [5 ]
Maslyar, Daniel [5 ]
Burris, Howard [4 ]
机构：
[1] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA
[2] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA
[3] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
NSCLC; ADC; Phase I; NaPi2b;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-014
引用
收藏
页码：S1190 / S1191
页数：2
相关论文
共 22 条
  • [1] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study
    Martin Sebastian
    Bernward Passlick
    Hilke Friccius-Quecke
    Michael Jäger
    Horst Lindhofer
    Frank Kanniess
    Rainer Wiewrodt
    Eckhard Thiel
    Roland Buhl
    Alexander Schmittel
    Cancer Immunology, Immunotherapy, 2007, 56 : 1637 - 1644
  • [2] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3):: a phase I study
    Sebastian, Martin
    Passlick, Bernward
    Friccius-Quecke, Hilke
    Jaeger, Michael
    Lindhofer, Horst
    Kanniess, Frank
    Wiewrodt, Rainer
    Thiel, Eckhard
    Buhl, Roland
    Schmittel, Alexander
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) : 1637 - 1644
  • [3] Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study
    Pujol, Jean-Louis
    De Pas, Tommaso
    Rittmeyer, Achim
    Vallieres, Eric
    Kubisa, Bartosz
    Levchenko, Eugeny
    Wiesemann, Sebastian
    Masters, Gregory A.
    Shen, Robert
    Tjulandin, Sergei A.
    Hofmann, Hans-Stefan
    Vanhoutte, Nicolas
    Salaun, Bruno
    Debois, Muriel
    Jarnjak, Silvija
    Alves, Pedro Miguel De Sousa
    Louahed, Jamila
    Brichard, Vincent G.
    Lehmann, Frederic F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (12) : 2208 - 2217
  • [4] A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2
    Kim, Young Hak
    Kubota, Kaoru
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Ohmatsu, Hironobu
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (09) : 576 - 581
  • [5] Gemcitabine and interferon-α2b in solid tumors:: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer
    Fuxius, S
    Mross, K
    Mansouri, K
    Unger, C
    ANTI-CANCER DRUGS, 2002, 13 (09) : 899 - 905
  • [6] A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer
    Wu, Guolan
    Wu, Lihua
    Zhou, Huili
    Lin, Meihua
    Peng, Ling
    Wang, Yina
    Zhai, You
    Hu, Xingjiang
    Zheng, Yunliang
    Lv, Duo
    Liu, Jian
    Shentu, Jianzhong
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402
    Miyauchi, Eisaku
    Tanaka, Hisashi
    Nakamura, Atsushi
    Harada, Toshiyuki
    Nakagawa, Taku
    Morita, Mami
    Jingu, Daisuke
    Kuda, Tomoya
    Gamou, Shunichi
    Saito, Ryota
    Inoue, Akira
    THORACIC CANCER, 2021, 12 (21) : 2886 - 2893
  • [8] Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
    Stathis, Anastasios
    Flinn, Ian W.
    Madan, Sumit
    Maddocks, Kami
    Freedman, Arnold
    Weitman, Steven
    Zucca, Emanuele
    Munteanu, Mihaela C.
    Palomba, M. Lia
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 869 - 876
  • [9] Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
    Anastasios Stathis
    Ian W. Flinn
    Sumit Madan
    Kami Maddocks
    Arnold Freedman
    Steven Weitman
    Emanuele Zucca
    Mihaela C. Munteanu
    M. Lia Palomba
    Investigational New Drugs, 2018, 36 : 869 - 876
  • [10] Clinical Activity of Lorlatinib in Patients with ROS1+Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6
    Ou, S.
    Shaw, A.
    Riely, G.
    Chiari, R.
    Bauman, J.
    Clancy, J.
    Thurm, H.
    Peltz, G.
    Abbattista, A.
    Solomon, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S322 - S323
123